0001104659-26-060333
SEC filingQ1 FY2026 results showed operating loss widening to -$8.8M from -$8.2M due to higher R&D and personnel costs, while net loss surged to -$115.3M and diluted EPS to -$3.16, driven by non-operating factors. Operating cash use improved to -$5.8M free cash flow amid ongoing negative cash flows.
Armata Pharmaceuticals reported Q1 FY2026 operating income of -$8.8 million, a 7.3% widening from -$8.2 million in the prior year quarter. This increase in loss reflects higher research and development expenses, primarily driven by an uptick in lab supplies tied to preparations for the end-of-Phase 2 FDA meeting and engineering runs. Personnel-related costs also contributed, with increases in incentive compensation, salaries, wages, employee benefits, and stock-based compensation. These investments underscore the company's commitment to advancing its bacteriophage therapeutic pipeline, including AP-SA02 for S. aureus bacteremia, where the high-titer formulation offers potential pediatric expansion via small-volume dosing.
Net income swung sharply to -$115.3 million from -$6.5 million year-over-year, pushing diluted EPS to -$3.16 from -$0.20—a 1480% deterioration. This reflects Armata's ongoing pattern of net losses and negative operating cash flows since inception, as noted in management discussion. While specific drivers beyond operating losses are not quantified in available data, the results highlight the financial volatility inherent in clinical-stage biopharma development, where R&D intensity precedes revenue generation.
Cash flow dynamics showed resilience in operations, with net cash provided by operating activities at -$5.8 million, an improvement from -$7.6 million prior year. This moderation likely stems from non-cash adjustments and tighter working capital management, helping preserve liquidity for general corporate purposes and product candidate advancement. Capital expenditures fell to $63 thousand from $99 thousand, signaling restrained spending on lab equipment amid broader expense controls. Resulting free cash flow of -$5.8 million aligns with the company's negative cash flow profile.